UK Markets close in 2 hrs 8 mins

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.40+0.79 (+10.38%)
At close: 04:00PM EDT
8.35 -0.05 (-0.60%)
Pre-market: 08:39AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.02
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 318.93
52-week low 37.40
50-day moving average 311.40
200-day moving average 312.80

Share statistics

Avg vol (3-month) 3696.18k
Avg vol (10-day) 31.11M
Shares outstanding 553.46M
Implied shares outstanding 6N/A
Float 844.95M
% held by insiders 116.37%
% held by institutions 158.25%
Shares short (13 Jan 2022) 41.74M
Short ratio (13 Jan 2022) 43.85
Short % of float (13 Jan 2022) 43.32%
Short % of shares outstanding (13 Jan 2022) 43.26%
Shares short (prior month 14 Dec 2021) 42.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 315 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 17.76%
Operating margin (ttm)16.92%

Management effectiveness

Return on assets (ttm)7.63%
Return on equity (ttm)14.24%

Income statement

Revenue (ttm)134.3M
Revenue per share (ttm)2.69
Quarterly revenue growth (yoy)118.80%
Gross profit (ttm)27.23M
Net income avi to common (ttm)23.85M
Diluted EPS (ttm)0.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)144.19M
Total cash per share (mrq)2.7
Total debt (mrq)4.09M
Total debt/equity (mrq)1.97
Current ratio (mrq)11.04
Book value per share (mrq)4.13

Cash flow statement

Operating cash flow (ttm)23.25M
Levered free cash flow (ttm)14.54M